Search
Birtamimab
go.drugbank.com/drugs/DB16414InvestigationalBirtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
Cardiopet
go.drugbank.com/drugs/DB18913InvestigationalCardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).
PR1 leukemia peptide vaccine
go.drugbank.com/drugs/DB15276InvestigationalPR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).
SAR-125844
go.drugbank.com/drugs/DB15382InvestigationalSAR-125844 is under investigation in clinical trial NCT01391533 (Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors).
Rabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
ATG-101
go.drugbank.com/drugs/DB17162Investigational, while delivering enhanced anti-tumor activity, with an improved safety profile. … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors
VPM4001
go.drugbank.com/drugs/DB05089ExperimentalVPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.
L-cysteic acid
go.drugbank.com/drugs/DB03661ExperimentalL-cysteic acid is a beta-sulfoalanine. It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate.
Maropitant
go.drugbank.com/drugs/DB11427ExperimentalVet approvedMaropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.
Subasumstat
go.drugbank.com/drugs/DB16406Investigationalor Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)). … Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced